{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:43:04Z","timestamp":1787740984137,"version":"build-2784847793"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-026-12328-7","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:04:58Z","timestamp":1770984298000},"page":"4318-4320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ESR Innovation in Focus: High-relaxivity gadolinium-based contrast agents"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0149-0801","authenticated-orcid":false,"given":"Carlo A.","family":"Mallio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Roditi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart J.","family":"van der Molen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"12328_CR1","doi-asserted-by":"publisher","unstructured":"Runge VM (2025) Current research and development in the field of magnetic resonance contrast media. Invest Radiol. https:\/\/doi.org\/10.1097\/rli.0000000000001206","DOI":"10.1097\/rli.0000000000001206"},{"key":"12328_CR2","doi-asserted-by":"publisher","unstructured":"Gruendemann S, Frenzel T, Lohrke J et al (2025) In vitro and in vivo stability assessment of the novel, macrocyclic gadolinium-based contrast agent gadoquatrane. Invest Radiol. https:\/\/doi.org\/10.1097\/rli.0000000000001195","DOI":"10.1097\/rli.0000000000001195"},{"key":"12328_CR3","doi-asserted-by":"publisher","unstructured":"Valencia S, Cortes-Albornoz MC, Ferracioli SF et al (2025) Gadopiclenol versus gadoterate meglumine for pediatric brain MRI: an intraindividual comparison of contrast enhancement. AJR Am J Roentgenol. https:\/\/doi.org\/10.2214\/ajr.25.33201","DOI":"10.2214\/ajr.25.33201"},{"key":"12328_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/RLI.0000000000000563","volume":"54","author":"C Robic","year":"2019","unstructured":"Robic C, Port M, Rousseaux O et al (2019) Physicochemical and pharmacokinetic profiles of gadopiclenol: a new macrocyclic gadolinium chelate with high T1 relaxivity. Invest Radiol 54:475\u2013484. https:\/\/doi.org\/10.1097\/RLI.0000000000000563","journal-title":"Invest Radiol"},{"key":"12328_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/vhrm.2008.04.01.1","volume":"4","author":"M Goyen","year":"2008","unstructured":"Goyen M (2008) Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag 4:1\u20139. https:\/\/doi.org\/10.2147\/vhrm.2008.04.01.1","journal-title":"Vasc Health Risk Manag"},{"key":"12328_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mri.2021.11.011","volume":"86","author":"M \u00c5kesson","year":"2022","unstructured":"\u00c5kesson M, Lehti L, Leander P et al (2022) Long-term safety of gadofosveset in clinical practice. Magn Reson Imaging 86:70\u201373. https:\/\/doi.org\/10.1016\/j.mri.2021.11.011","journal-title":"Magn Reson Imaging"},{"key":"12328_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/RLI.0000000000000431","volume":"53","author":"CC Quattrocchi","year":"2018","unstructured":"Quattrocchi CC, Errante Y, Mallio CA et al (2018) Effect of age on high T1 signal intensity of the dentate nucleus and globus pallidus in a large population exposed to gadodiamide. Invest Radiol 53:214\u2013222. https:\/\/doi.org\/10.1097\/RLI.0000000000000431","journal-title":"Invest Radiol"},{"key":"12328_CR8","doi-asserted-by":"publisher","unstructured":"Fretellier N, Id\u00e9e J-M, Rasschaert M et al (2025) Gadolinium deposition in bone tissues after contrast-enhanced magnetic resonance imaging: a comprehensive review. Invest Radiol. https:\/\/doi.org\/10.1097\/rli.0000000000001208","DOI":"10.1097\/rli.0000000000001208"},{"key":"12328_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2025.112322","volume":"191","author":"T Marth","year":"2025","unstructured":"Marth T, Froehlich JM, Nanz D, Sutter R (2025) Gadolinium concentration dependent signal enhancement profiles using routine clinical sequences with gadopiclenol, gadoterate, gadobutrol, and gadoxetate at 1.5, 3 and 7 Tesla. Eur J Radiol 191:112322. https:\/\/doi.org\/10.1016\/j.ejrad.2025.112322","journal-title":"Eur J Radiol"},{"key":"12328_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/rli.0000000000000944","volume":"58","author":"LA Loevner","year":"2023","unstructured":"Loevner LA, Kolumban B, Hut\u00f3czki G et al (2023) Efficacy and safety of gadopiclenol for contrast-enhanced MRI of the central nervous system: the PICTURE randomized clinical trial. Invest Radiol 58:307\u2013313. https:\/\/doi.org\/10.1097\/rli.0000000000000944","journal-title":"Invest Radiol"},{"key":"12328_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/RLI.0000000000000865","volume":"57","author":"E Jurkiewicz","year":"2022","unstructured":"Jurkiewicz E, Tsvetkova S, Grinberg A, Pasquiers B (2022) Pharmacokinetics, safety, and efficacy of gadopiclenol in pediatric patients aged 2 to 17 years. Invest Radiol 57:510\u2013516. https:\/\/doi.org\/10.1097\/RLI.0000000000000865","journal-title":"Invest Radiol"},{"key":"12328_CR12","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222612","volume":"308","author":"C Kuhl","year":"2023","unstructured":"Kuhl C, Cs\u0151szi T, Piskorski W et al (2023) Efficacy and safety of half-dose gadopiclenol versus full-dose gadobutrol for contrast-enhanced body MRI. Radiology 308:e222612. https:\/\/doi.org\/10.1148\/radiol.222612","journal-title":"Radiology"},{"key":"12328_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/rli.0000000000000889","volume":"57","author":"J Lohrke","year":"2022","unstructured":"Lohrke J, Berger M, Frenzel T et al (2022) Preclinical profile of gadoquatrane: a novel tetrameric, macrocyclic high relaxivity gadolinium-based contrast agent. Invest Radiol 57:629\u2013638. https:\/\/doi.org\/10.1097\/rli.0000000000000889","journal-title":"Invest Radiol"},{"key":"12328_CR14","unstructured":"Bayer. Bayer\u2019s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies. Available via https:\/\/www.bayer.com\/media\/en-us\/bayers-investigational-mri-contrast-agent-gadoquatrane-meets-primary-and-main-secondary-endpoints-in-pivotal-phase-iii-studies\/. Accessed 17 Nov 2025"},{"key":"12328_CR15","doi-asserted-by":"publisher","unstructured":"Fadini T, Sutter G, Klein S et al (2025) Pharmacokinetics, safety, and dialyzability of gadoquatrane in patients with impaired renal function: a comprehensive investigation using clinical trial data, modeling and simulation, and in vitro data. Invest Radiol. https:\/\/doi.org\/10.1097\/rli.0000000000001191","DOI":"10.1097\/rli.0000000000001191"},{"key":"12328_CR16","unstructured":"Bayer (2025) RSNA25: Pediatric Study for Bayer's investigational MRI contrast agent gadoquatrane meets primary and secondary endpoints. Available via https:\/\/bayer2019tf.q4web.com\/news\/news-details\/2025\/RSNA25-Pediatric-Study-for-Bayers-Investigational-MRI-Contrast-Agent-Gadoquatrane-Meets-Primary-and-Secondary-Endpoints\/default.aspx. Accessed 19 Dec 2025"},{"key":"12328_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/RLI.0000000000000983","volume":"58","author":"CA Mallio","year":"2023","unstructured":"Mallio CA, Radbruch A, Deike-Hofmann K et al (2023) Artificial intelligence to reduce or eliminate the need for gadolinium-based contrast agents in brain and cardiac MRI: a literature review. Invest Radiol 58:746\u2013753. https:\/\/doi.org\/10.1097\/RLI.0000000000000983","journal-title":"Invest Radiol"},{"key":"12328_CR18","unstructured":"Bracco (2025) CE mark of AiMIFY\u2122 software for enhanced MRI in Europe. Available via https:\/\/www.bracco.com\/article\/ce-mark-aimifytm-software-enhanced-mri-europe. Accessed 17 Nov 2025"},{"key":"12328_CR19","doi-asserted-by":"publisher","unstructured":"Spinazzi A, Lancelot E, Vitali L et al (2025) Safety of gadopiclenol after its first year of clinical use. Invest Radiol. https:\/\/doi.org\/10.1097\/RLI.0000000000001144","DOI":"10.1097\/RLI.0000000000001144"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12328-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12328-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12328-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:25:55Z","timestamp":1779798355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12328-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["12328"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12328-7","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Carlo A. Mallio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies: Carlo A. Mallio: none. Giles Roditi: served as the United Kingdom Principal Investigator for the Phase III Gadoquatrane study supported by Bayer, without receiving personal remuneration. Aart J. van der Molen: none.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}